에서 실시간으로 운영 중이에요! 자세히 알아보기
238.97 USD
-3.26
1.35%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
238.97
0.00
0%
1일
-1.35%
5일
3.12%
1개월
4.7%
3개월
17.86%
6개월
6.34%
연초 이후
-2.39%
1년
-11.49%
5년
-7.01%
10년
272.34%
 

소개: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

직원 수: 11,370

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 22.2%
중립 70.4%
부정적 7.4%
긍정적
Seeking Alpha
5일 전
Top 50 High-Quality Dividend Growth Stocks For October 2026
I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.
Top 50 High-Quality Dividend Growth Stocks For October 2026
중립
GlobeNewsWire
15일 전
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
긍정적
Seeking Alpha
15일 전
Top 25 High-Growth Dividend Stocks For October 2026
The October 2026 Top 25 High-Growth Dividend Stocks list targets quality companies trading 31% below intrinsic value, with a projected 22.53% annual return. The list's average starting dividend yield is 1.51%, and the companies have grown dividends at 18.81% annually over five years. Stocks are categorized into Deep Value, Growth At A Price, and Balanced Opportunities, supporting diverse investment strategies based on valuation and growth.
Top 25 High-Growth Dividend Stocks For October 2026
중립
MarketBeat
25일 전
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.
ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand
긍정적
Barrons
지난달
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
Setbacks for competitors have positioned ResMed to capture more market share.
Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.
중립
Seeking Alpha
지난달
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
부정적
Zacks Investment Research
지난달
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
중립
Seeking Alpha
지난달
ResMed: A Significant Upside Despite The Perceived Risk
ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.
ResMed: A Significant Upside Despite The Perceived Risk
중립
PRNewsWire
지난달
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
중립
GlobeNewsWire
지난달
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. (“ResMed” or the “Company”) (NYSE: RMD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
Lightweight Charts™를 사용해 가격 차트를 구현했어요.